News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Salix Pharmaceuticals, Ltd. (SLXP) Buys IP Rights Connected to Top Moneymaker


5/31/2013 8:25:23 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Salix Pharmaceuticals, Raleigh’s largest homegrown drug company, acquired various intellectual property rights for products that would relate to its highest revenue drug. Salix (Nasdaq: SLXP) announced Thursday it bought one patent application and one issued patent related to rifaximin, a drug which Salix sells under the brand name Xifaxan and which recorded $514 million in sales in 2012, or 70 percent of total revenues.

Help employers find you! Check out all the jobs and post your resume.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES